Skip to main content

Table 1 Characteristics of the genotyped patients

From: Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

  Patients with optimal response at 6 months (n = 32) Patients with non-optimal response at 6 months (n = 30) p-value
Age, years, median (range) 39 (19–66) 52 (21–71) 0.0768
Gender 0.5940
 Female, n (%) 15 (55.6) 12 (44.4)  
 Male, n (%) 17 (48.6) 18 (51.4)
Sokal group
 Low, n (%) 21 (65.6) 4 (13.3)*  
 Intermediate, n (%) 6 (18.8) 1 (3.3)*
 High, n (%) 5 (15.6) 2 (6.7)*
TKI therapy
 First line, n (%) 29 (90.6) 30 (100)  
  Imatinib 400 mg, n (%) 25 (78.1) 28 (93.3)
  Imatinib 600 mg, n (%)   2 (6.7)
  Nilotinib 400–600 mg, n (%) 3 (9.4)  
  Dasatinib, 100 mg, n (%) 1 (3.1)  
 Second line, n (%) 3 (9.4) 0 (0)
  Nilotinib 400–600 mg, n (%) 1 (3.1)**  
  Dasatinib, 100 mg, n (%) 2 (6.3)**  
  1. *Sokal score data for 23 patients were not available
  2. **patients were switched to the second line therapy due to imatinib intolerance or sub-optimal response at 3 months
  3. TKI tyrosine kinase inhibitor